cagrilintide coa (5 mg) + Semaglutide (5 mg) Cagrilintide 10mg – Research-Grade Compound

How does an oral BPC-157 capsule differ from injectable BPC-157

Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]

Current research has not established significant hormone-related side effects specific to women

The activation of VEGFR2-Akt-eNOS and Src-Caveolin-1-eNOS signaling pathways provides unified vascular protection across organ systems

INFORMATION What is BPC-157 (20mg)

Drug Interactions No specific drug interactions have been documented for BPC-157